The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA

被引：0
|
作者：
Bansback, NJ
Brennan, A
Sengupta, N
Pang, F
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [11] Adalimumab (HUMIRA®) monotherapy significantly improves health utility in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - 392
  • [12] Workplace impacts of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA)
    Birnbaum, Howard
    Pike, Crystal
    Kaufman, Rebecca
    Schiller, Matthew
    Shi, Lizheng
    Sun, Peter
    Ray, Saurabh
    Cifaldi, Mary
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S459 - S459
  • [13] Cost-effectiveness of apremilast in moderate to severe psoriasis in the UK
    Mughal, Farhan
    Barker, Jonathan
    Cawston, Helene
    Damera, Vidya
    Bewley, Anthony
    Morris, James
    Shaw, Tim
    Tencer, Tom
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB243 - AB243
  • [14] The cost-effectiveness of adalimumab (HUMIRA™, Abbott) in patients with rheumatoid arthritis:: A Swedish analysis.
    Bansback, NJ
    Brennan, A
    Ghatnekar, O
    Sengupta, N
    Chang, KY
    Hansen, M
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S611 - S611
  • [15] The cost effectiveness of etanercept in patients with severe as in the UK
    Ara, R. M.
    Reynolds, A. V.
    Conway, P.
    Brennan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 273 - 274
  • [16] The cost utility of adalimumab (HUMIRA®) and infliximab (REMICADE) in the treatment of patients with early rheumatoid arthritis (RA):: US analysis
    Davies, AS
    Hutton, J
    Cifaldi, MA
    Pang, F
    Spencer-Green, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 393 - 393
  • [17] Humira® (Adalimumab) Approved in Europe for the treatment of Moderate-Severe Crohn's disease
    Nienstedt, Maren
    VISZERALMEDIZIN, 2012, 28 (05): : 356 - 356
  • [18] COST-EFFECTIVENESS OF RITUXIMAB VS ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    Bynum, L. A.
    Joshi, N.
    VALUE IN HEALTH, 2010, 13 (03) : A126 - A126
  • [19] COST-EFFECTIVENESS OF TOCILIZUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN THE TREATMENT OF SEVERE ACTIVE RA
    Carlson, J. J.
    Ogale, S.
    Dejonckheere, F.
    Sullivan, S. D.
    VALUE IN HEALTH, 2012, 15 (07) : A447 - A447
  • [20] The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
    Incerti, Devin
    Hernandez, Ervant J. Maksabedian
    Tkacz, Joseph
    Jansen, Jeroen P.
    Collier, David
    Gharaibeh, Mahdi
    Moore-Schiltz, Laura
    Stolshek, Bradley S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (10): : 1236 - 1242
12345